UroGen Pharma Ltd —— 季度财务数据 (NASDAQ:URGN) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

经营活动产生的现金 -13.62 M-42.02 M-39.83 M-42.27 M-38.33 M -162.44 M 投资活动产生的现金 60.62 M-25.96 M28.41 M31.4 M27.72 M 61.56 M 融资活动产生的现金 71 K34 K296 K8.27 M31.32 M 39.92 M 自由现金流 -13.73 M-42.07 M-39.97 M-42.36 M-38.34 M -162.73 M

新闻

UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers

UroGen Pharma在TD Cowen会议上展示战略增长与创新

UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation

Oppenheimer上调UroGen Pharma股票目标价至34美元,看好Zusduri销售表现

Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales

Oppenheimer重申UroGen Pharma股票评级,Zusduri销售强劲

Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales

UroGen Pharma第四季度业绩不及每股收益和营收预期

Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts

Palantir and AeroVironment among market cap stock movers on Monday

Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates

UroGen PharmaQ1每股收益及营收逊于预期